A new systematic review has taken stock of ketamine’s liver safety in mood and anxiety treatment, and its headline finding is reassuring. But the fine print is where the real signal sits. The desk has covered ketamine’s expansion into treatment-resistant depression, suicidality, OCD, substance use, and pain, along with the engineered successors built to keep its benefit while shedding its baggage. This review is a careful reminder of the counterweight to that expansion story.
What the Review Found
Pooling randomized trials, the review reports that at the dosing regimens typical of mood-disorder treatment, ketamine produces mostly mild, transient elevations in liver enzymes. Serious hepatotoxicity, meaning significant liver damage, appears rare. Across roughly 879 trial participants there were 75 hepatic adverse events, mostly temporary rises in liver enzymes called aminotransferases, and none met Hy’s Law, the regulatory threshold for predicting severe drug-induced liver injury. On its face, that is a clean bill: at the doses psychiatry uses, the liver is not where ketamine’s danger lives.
The Assumption Holding Up the Headline
The reassurance rests on a dose premise, and the review is honest about it. Nearly all the documented cases of clinically significant hepatobiliary injury, damage to the liver and bile ducts, have occurred at substantially greater cumulative exposure than mood-disorder regimens deliver. The severe end of the literature is real and ugly. Chronic exposure can produce a cholestatic injury, a blockage of bile flow, resembling sclerosing cholangitis, with bile-duct dilation and, in the worst cases, fibrosis, or scarring of liver tissue. This kind of damage tends to arise from sustained use, not a single dose. It clusters among heavy recreational users and high-cumulative-dose chronic-pain patients. The psychiatric safety case is essentially that mood-disorder dosing stays below the exposure where the serious damage shows up.
That assumption is exactly what the rest of the ketamine story is straining. The desk has tracked this whole arc: expansion into more indications, maintenance and repeated dosing to sustain response, and a booming off-label intravenous clinic ecosystem operating with light oversight. Together, they move patients toward higher cumulative exposure over time. A retrospective case series has already linked repeated or continuous medically supervised ketamine to hepatobiliary events, most of them in repeated-dosing pain settings. The reassuring finding and the worrying trajectory are the same fact viewed from two ends: safe at the dose we use today, with the field steadily increasing the dose patients accumulate.
The Case for Taking Monitoring Seriously
This is the safety question maturing in step with the treatment. Health authorities already recommend periodic liver-function monitoring during chronic or intermittent ketamine dosing. This review hands clinicians the evidence to take that seriously instead of treating it as boilerplate. There is also a concrete management option in reserve: ursodeoxycholic acid, a bile-acid drug, has shown promise for treating ketamine-induced cholestatic injury. It also feeds two threads the desk has open. It is one more cumulative-exposure harm, alongside the better-known bladder and urothelial toxicity, damage to the lining of the urinary tract, that defines the ceiling on how freely ketamine can be dosed as it expands. And it adds to the rationale for the cleaner successors, the hydroxynorketamine, deuterated, and R-enantiomer programs, three families of chemically modified ketamine, built to deliver the antidepressant effect at lower exposure and risk. A review that maps where liver injury starts is, in part, mapping the exposure ceiling those successors are trying to lift.
Where This Reassurance Runs Out
The caveats cut in both directions. The trial data is reassuring and should not be inflated into alarm. At studied psychiatric doses, serious liver injury was not seen. A population-based pharmacovigilance analysis, a review of real-world adverse-event reports, did not find ketamine disproportionately associated with most hepatobiliary harms relative to a known hepatotoxin, a drug already established to damage the liver. At the same time, trial populations are selected and time-limited, while real-world maintenance use runs longer and messier than a trial. The severe cases in the literature are a warning about where the tail leads, not proof that psychiatric use reaches it. The mechanism of ketamine’s hepatobiliary toxicity is still not well understood, which makes individual susceptibility hard to predict. And the benefit is not in question; this is an argument for monitoring and for dose discipline as use scales, not for backing away from a treatment that works rapidly where little else does.
A Reassurance With an Expiration Date
The honest reading is that ketamine’s liver risk is low at the doses psychiatry currently uses and real at the cumulative exposures its own expansion keeps nudging toward. The review’s reassurance is conditional on a dose ceiling. The breadth thesis, the maintenance-dosing logic, and the lightly regulated clinic boom are all pressure on that ceiling. The takeaway is not fear. Liver monitoring belongs in the standard of care as firmly as the field’s enthusiasm for new indications, and the exposure question deserves to be tracked as carefully as the efficacy that keeps generating the headlines.